Home Current Issue Previous Issues Published Ahead-of-Print Collections For Authors Journal Info
Skip Navigation LinksHome > January 28, 2013 - Volume 27 - Issue 3 > Microbial translocation and AIDS-associated lymphomas: crux...
AIDS:
doi: 10.1097/QAD.0b013e32835cba91
Editorial Comments

Microbial translocation and AIDS-associated lymphomas: crux of the problem

Allam, Ossama; Samarani, Suzanne; Ahmad, Ali

Free Access
Article Outline
Collapse Box

Author Information

Laboratory of Innate Immunity, Centre Hospitalier Universitaire (CHU) Ste-Justine Research Center/Department of Microbiology & Immunology, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada.

Correspondence to Ali Ahmad DVM, MSc, PhD (Cornell), CHU Ste-Justine Research Center, 3175 Cote Ste-Catherine, Montreal, QC H3T 1C5, Canada. Tel: +1 514 345 4931x6157; fax: +1 514 345 4801; e-mail: ali.ahmad@recherche-ste-justine.qc.ca

Received 6 November, 2012

Accepted 16 November, 2012

In this issue of AIDS, Marks et al.[1] have reported significant associations between markers of microbial translocation and increased risk for non-Hodgkin's lymphoma (NHL) in HIV-infected individuals. The authors examined prediagnostic blood samples from NHL and non-NHL HIV-infected individuals for different markers of microbial translocation. The results show that elevated plasma levels of sCD14 associated independently with 2.5-fold increased risk for NHL. The authors used Limulus Amebocyte Lysate Assay for measuring lipopolysaccharide (LPS). As plasma/serum contains substances that interfere with the assay, the authors measured percentage recovery of LPS from each sample after spiking it with LPS. Considering the samples from which they recovered the recommended (50–200) percentage of the spiked LPS, they found significant associations of the above-median values with increased (3.0-fold) risk for NHL. These results suggest, for the first time, an etiologic role of microbial translocation across gut mucosa in lymphomagenesis in HIV-infected individuals.

Increased plasma LPS concentrations occurring in chronic HIV infection, described first in 2006 [2], result from defective intestinal barrier in the virus-infected individuals. Many factors are likely to contribute towards this defect: direct effect of HIV-1, gp-120, defective mucosal immune function due to depletion of gut-homing α4β7+ CD4+ T cells in the gut mucosa, and so on [3,4]. The virus is known to replicate massively and cause depletion of CD4+ T cells in the gut within the first few weeks of the infection. The virus and its products induce this defect at least in part through induction of proinflammatory mediators, for example, TNF-α, IFN-γ, IL-6, and the like. These mediators destabilize perijunctional actomyosin cytoskeleton associated with tight junctions and subjacent adherens junctions (collectively known as apical junctional complex; APC) via activating nonmuscle-myosin light chain kinase and/or rho-like kinases. The kinases disturb normal homeostatic polymerization and depolymerization (treadmilling) of F-actin. The defective junctions are accompanied by changes in the expression and spatial distribution of various junction proteins (ZO-1, claudins, occludin, E-cadheins, etc). APC defines cell polarity and controls diffusion of molecules through interepithelial (paracellular) spaces [5]. The defective APC and consequently increased paracellular permeability results in translocation of bacterial products (LPS, flagellin, DNA, etc) into body tissues and circulation. Barring some in-vitro studies, little is known about the exact defects occurring in vivo in APC in the intestines of HIV-infected persons. In addition to increased paracellular intestinal permeability, certain proinflammatory mediators (e.g. TNF-α) and viral proteins (e.g. Tat) cause death of intestinal epithelial cells and may result in localized denuded mucosal surfaces [6]. Bacterial products can easily diffuse through such surfaces [5]. Bacteria can also attach to the denuded surfaces and enter into body tissues. Moreover, depletion of CD4+ T cells in the gut mucosa also results in defective mucosal immunity. This may lead to changes in the composition of gut flora resulting in their dysbiosis with the host, stimulating local inflammation and further aggravating microbial translocation. Translocated microbial products induce immune activation and systemic inflammation by activating a variety of pattern recognition receptors (e.g. toll-like receptors, retinoic acid-induced gene-like helicases, inflammasomes, etc.) expressed by different body cells. Chronic inflammation is increasingly being realized as a promoter of malignancy. It promotes tumorigenesis by inducing DNA-damaging oxidative and nitrative stress and suppressing DNA repair [7]. The main mediators of inflammation, cytokines and chemokines, play a dual role in this process. Although they suppress tumors by enhancing immune responses, they also promote them by inducing cell proliferation, angiogenesis, metastasis and genomic instability. In this context, the association between markers of microbial translocation and risk for NHL in HIV-infected individuals, demonstrated by Marks et al.[1], is a welcome news, and highlights the role of chronic inflammation in the cause of lymphomagenesis. Increased microbial translocation has been observed in hematological malignancies; however, it was thought to result mainly from chemotherapy [8].

HIV-induced AIDS is accompanied by increased incidence of different types of cancers including NHL, Kaposi sarcoma, invasive cervical cancer, and primary central nervous system lymphoma. Their occurrence is considered as an AIDS-defining condition. Tumor-promoting opportunistic infections like HHV-8 and Epstein–Barr virus play a role in the development of these AIDS-defining cancers. Since the advent of combination antiretroviral therapy (cART) in mid-1990s, the incidence of opportunistic infections has decreased considerably, and so has the incidence of these so-called ‘AIDS-defining’ cancers. However, the incidence of NHL still remains two-fold to three-fold higher in HIV-infected individuals undergoing cART [9]. Ironically, the incidence of so-called non-AIDS-defining cancers like Hodgkin's lymphoma, cancer of lung, liver, kidney, anus, skin, head and neck has, compared with the general population, increased in the cART-treated patients. The potential causes include coinfection with oncogenic viruses, tobacco and alcohol consumption, psychological stress, cART, and HIV itself [9]. In this regard, the Marks et al.[1] study highlights the role of defective intestinal barrier function, microbial translocation and consequently low-grade chronic inflammation in the increased incidence of these cancers. It is tempting to speculate that undetectable residual viral replication occurring in the gut mucosa is the cause of this defective intestinal barrier function. Gut mucosa is the site wherein the viral reservoir establishes itself early in the course of the infection before initiation of the therapy [10]. It would be interesting to investigate intestinal barrier function in cART-treated, HIV-infected individuals, and examine the potential role of cART as a contributing factor toward increased intestinal permeability.

In the final analysis, low-grade chronic inflammation induced by microbial translocation is the crux of the problem in increased incidence of NHL and possibly other non-AIDS-defining cancers in cART-treated HIV-infected individuals. It may also be an underlying cause in other non-AIDS ailments like frailty, premature aging, and atherosclerosis in these patients. An immediate solution to the problem lies in resorting to anti-inflammatory and intestinal permeability-enhancing measures. A longer term solution, albeit a difficult one, remains finding means of depleting residual viral reservoirs, especially from the gut mucosa.

Back to Top | Article Outline

Acknowledgements

We thank the colleagues who participated in these discussions.

Back to Top | Article Outline
Conflicts of interest

The authors declare no conflict of interest

Back to Top | Article Outline

References

1. Marks MA, Rabkin CS, Engels EA, Kopp W, Rager H, Goedert JJ, et al.Markers of microbial translocation and risk of AIDS-related lymphoma. AIDS 2012; 27:469–474.

2. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365–1371.

3. Nazli A, Chan O, Dobson-Belaire WN, Ouellet M, Tremblay MJ, Gray-Owen SD, et al. Exposure to HIV-1 directly Impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog 2010; 6:e1000852.

4. Sattentau Q. Human immunodeficiency virus may direct its assault on gut-associated CD4+ T cells by means of the gut-homing integrin α4β7. Nat Immunol 2008; 9:225–227.

5. Ivanov AI, Parkos CA, Nusrat A. Cytoskeletal regulation of epithelial barrier function during inflammation. Am J Pathol 2010; 177:512–524.

6. Buccigrossi V, Laudiero G, Nicastro E, Miele E, Esposito F, Guarino A. The HIV-1 transactivator factor (Tat) induces enterocyte apoptosis through a redox mediated mechanism. PLoS One 2011; 6:e29436.

7. Sethi G, Shanmugam MK, Ramachandran L, Kumar AP, Tergaonkar V. Multifaceted link between cancer and inflammation. Biosci Rep 2012; 32:1–15.

8. Ellis M. Preventing microbial translocation in haematological malignancy. Brit J Haematol 2004; 125:282–293.

9. Deeken JF, Tjen-A-Looi A, Rudek MA, Okuliar C, Young M, Little RF, et al. The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis 2012; 55:1228–1235.

10. Dandekar S. Pathogenesis of HIV in the gastrointestinal tract. Curr HIV/AIDS Rep 2007; 4:10–15.

Keywords:

HIV; lipopolysacharide; non-Hodgkin lymphoma

© 2013 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.